Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity

Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via subcutaneous (SQ) injection, demonstrated a half-life of 21 days, supporting once-monthly administration in patients with obesity In multiple pre-clinical studies using the diet-induced obese (DIO) mouse model, ASC47 demonstrated healthy weight loss (muscle-preserving weight loss) Compared to semaglutide in a head-to-head pre-clinical study using a ...